CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of “Hold” from Brokerages

Shares of CareDx, Inc. (NASDAQ:CDNA) have earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $26.6667.

CDNA has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. BTIG Research raised their target price on CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Wells Fargo & Company lifted their price target on CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th.

Insider Buying and Selling

In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the sale, the chief executive officer directly owned 597,405 shares in the company, valued at approximately $12,641,089.80. The trade was a 3.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 29,636 shares of company stock valued at $625,949 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Fidelis Capital Partners LLC acquired a new position in shares of CareDx in the 4th quarter valued at $420,000. Jackson Creek Investment Advisors LLC bought a new position in shares of CareDx during the 4th quarter worth approximately $508,000. Royce & Associates LP boosted its stake in CareDx by 43.7% in the 4th quarter. Royce & Associates LP now owns 581,211 shares of the company’s stock valued at $10,950,000 after buying an additional 176,817 shares in the last quarter. Legal & General Group Plc grew its position in CareDx by 44.0% in the fourth quarter. Legal & General Group Plc now owns 230,482 shares of the company’s stock valued at $4,342,000 after acquiring an additional 70,480 shares during the period. Finally, Profund Advisors LLC grew its position in CareDx by 68.7% in the fourth quarter. Profund Advisors LLC now owns 33,867 shares of the company’s stock valued at $638,000 after acquiring an additional 13,788 shares during the period.

CareDx Trading Up 3.7%

CDNA opened at $20.19 on Tuesday. CareDx has a twelve month low of $10.96 and a twelve month high of $25.55. The stock has a market cap of $1.04 billion, a PE ratio of 16.97 and a beta of 2.51. The business’s 50 day moving average is $19.62 and its 200-day moving average is $16.20.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.